Krystal Biotech Inc, Affyimmune Therapeutics Inc, Rocket Pharmaceuticals Inc and Iovance Biotherapeutics Inc at Endpoints Webinar on Moving CGTx Clinical Development- Panel Transcript
Hello, everyone. Arslan Arif here with Endpoints News. And thanks for joining us today for Let's talk: Moving cell and gene therapy clinical development for 2023. We're sponsored by Precision ADVANCE and I'm excited to introduce today's expert panel. Joining us today, we have Dawn Buchanan, the VP of Clinical Operations at AffyImmune; Kinnari Patel, the President and COO of Rocket Pharmaceuticals. And also joining us is Ramona Repaczki-Jones, the Executive Director of Treatment Center Operations at Iovance Biotherapeutics; as well as Suma Krishnan, the President of Research and Development at Krystal Biotech. And moderating today's discussion is Teresa Pokladowski, the Regional VP of Clinical Business Solutions, North America at Precision for Medicine. If you have any questions during today's webinar, our panels have reserved some time for you for questions at the end. So just hit the Q&A button at the bottom of your screen as soon as you think of it. This webinar will be available on demand to rewatch or to share with your colleagues. And now I'm going to pass it up to Teresa to get it started. Teresa?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |